The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.” ...

Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes. This year, the European Society of Retina Specialists (EURETINA) held its ...

At the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow. At this year's meeting of the European Society of Retina Specialists ...

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some ...

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a noninvasive method for identifying high-risk patients through retinal analysis.

New research reveals significant inner retinal impairment in multiple sclerosis patients without optic neuritis, highlighting the need for further studies on macular health.

Recent research highlights inferred sensitivity mapping as a promising method to assess retinal function in geographic atrophy, enhancing clinical trial outcomes. A study reveals that ophthalmic ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Belite Bio, Inc, has completed enrollment in the PHOENIX trial. The PHOENIX study is a 24-month, randomized, double-masked, placebo-controlled, multicenter, pivotal phase 3 trial for this oral ...